Liao, K. P., Rist, P., Giles, J., Santacroce, L., Connelly, M. A., Glynn, R. J., Ridker, P., Tawakol, A., Bathon, J., & Solomon, D. H. (2024). Impact of RA treatment strategies on lipids and vascular inflammation in rheumatoid arthritis: a secondary analysis of the TARGET randomized active comparator trial. Arthritis Research & Therapy, 26(1). https://doi.org/10.1186/s13075-024-03352-3

Lyashchenko, A. K., Yu, Y., McMahon, D. J., Bies, R., Yin, M. T., & Cremers, S. (2022). Systemic exposure to hydroxychloroquine and its relationship with outcome in severely ill COVID‐19 patients in New York City. British Journal of Clinical Pharmacology, 89(1), 299–315. Portico. https://doi.org/10.1111/bcp.15489

Schultz, É., Atlani-Duault, L., Peretti-Watel, P., & Ward, J. K. (2022). Does the public know when a scientific controversy is over? Public perceptions of hydroxychloroquine in France between April 2020 and June 2021. Therapies, 77(5), 591–602. https://doi.org/10.1016/j.therap.2022.01.008

Almeida-Brasil, C. C., Hanly, J. G., Urowitz, M., Clarke, A. E., Ruiz-Irastorza, G., Gordon, C., Ramsey-Goldman, R., Petri, M., Ginzler, E. M., Wallace, D. J., Bae, S.-C., Romero-Diaz, J., Dooley, M. A., Peschken, C., Isenberg, D., Rahman, A., Manzi, S., Jacobsen, S., Lim, S., … Bernatsky, S. (2022). Flares after hydroxychloroquine reduction or discontinuation: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort. Annals of the Rheumatic Diseases, 81(3), 370–378. https://doi.org/10.1136/annrheumdis-2021-221295